GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » TFBS Bioscience Inc (ROCO:6939) » Definitions » Debt-to-Equity

TFBS Bioscience (ROCO:6939) Debt-to-Equity : 0.16 (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is TFBS Bioscience Debt-to-Equity?

TFBS Bioscience's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$119.8 Mil. TFBS Bioscience's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$76.4 Mil. TFBS Bioscience's Total Stockholders Equity for the quarter that ended in Dec. 2024 was NT$1,232.7 Mil. TFBS Bioscience's debt to equity for the quarter that ended in Dec. 2024 was 0.16.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for TFBS Bioscience's Debt-to-Equity or its related term are showing as below:

ROCO:6939' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03   Med: 0.06   Max: 0.11
Current: 0.1

During the past 5 years, the highest Debt-to-Equity Ratio of TFBS Bioscience was 0.11. The lowest was 0.03. And the median was 0.06.

ROCO:6939's Debt-to-Equity is ranked better than
70.68% of 191 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.23 vs ROCO:6939: 0.10

TFBS Bioscience Debt-to-Equity Historical Data

The historical data trend for TFBS Bioscience's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TFBS Bioscience Debt-to-Equity Chart

TFBS Bioscience Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Equity
0.08 0.05 0.04 0.11 0.16

TFBS Bioscience Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Debt-to-Equity Get a 7-Day Free Trial 0.04 0.03 0.11 0.10 0.16

Competitive Comparison of TFBS Bioscience's Debt-to-Equity

For the Diagnostics & Research subindustry, TFBS Bioscience's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TFBS Bioscience's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, TFBS Bioscience's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where TFBS Bioscience's Debt-to-Equity falls into.


;
;

TFBS Bioscience Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

TFBS Bioscience's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(119.779 + 76.379) / 1232.722
=0.16

TFBS Bioscience's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(119.779 + 76.379) / 1232.722
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TFBS Bioscience  (ROCO:6939) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

TFBS Bioscience Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of TFBS Bioscience's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

TFBS Bioscience Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » TFBS Bioscience Inc (ROCO:6939) » Definitions » Debt-to-Equity
Comparable Companies
ROCO:6615 TPE:6645 ROCO:7595 ROCO:6847 ROCO:6661 ROCO:4160 ROCO:4153 ROCO:1784 TMO DHR XSWX:LONN IDXX A IQV SHSE:603259 MTD WAT NTRA LH DGX
Traded in Other Exchanges
N/A
Address
No. 103, Lane 169, Kang-ning Street, 3rd Floor, Xizhi District, New Taipei, TWN
Website
https://www.tfbsbio.com
TFBS Bioscience Inc is a Contract Research Organization (CRO) providing biological testing in Taiwan. Its services include viral vector manufacturing for cell and gene therapy products and biosafety testing and product release testing for cell and gene therapy products, vaccines, and biologic products.

TFBS Bioscience Headlines

No Headlines